A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: 150 mg SuspensionDrug: 150 mg TabletDrug: 30 mg SuspensionDrug: 30 mg TabletDrug: 400 mg SuspensionDrug: 400 mg TabletDrug: 5 mg SuspensionDrug: 5 mg TabletDrug: 750 mg SuspensionDrug: 750 mg Tablet
- Registration Number
- NCT00857571
- Lead Sponsor
- Pfizer
- Brief Summary
The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Healthy male and female volunteers.
- Female volunteers have to be of non-childbearing potential
Exclusion Criteria
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Suspension 150 mg Suspension PF-02413873 suspension Suspension 30 mg Suspension PF-02413873 suspension Suspension 400 mg Suspension PF-02413873 suspension Suspension 5 mg Suspension PF-02413873 suspension Suspension 750 mg Suspension PF-02413873 suspension Tablet 150 mg Tablet PF-02413873 Phase 2 Tablets Tablet 30 mg Tablet PF-02413873 Phase 2 Tablets Tablet 400 mg Tablet PF-02413873 Phase 2 Tablets Tablet 5 mg Tablet PF-02413873 Phase 2 Tablets Tablet 750 mg Tablet PF-02413873 Phase 2 Tablets
- Primary Outcome Measures
Name Time Method Pharmacokinetics: Cmax, AUCinf June - July 2009
- Secondary Outcome Measures
Name Time Method Tmax, Tlag, AUClast, AUCt, t½, Frel. June-July 2009
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the pharmacokinetic profile of PF-02413873 in healthy volunteers as assessed in NCT00857571?
How does PF-02413873 compare to other PDE4 inhibitors in terms of plasma concentration and efficacy?
What are the molecular targets and mechanisms of action for PF-02413873 in preclinical studies?
Are there any biomarkers identified that correlate with dose response of PF-02413873 in Phase 1 trials?
What adverse events were observed with PF-02413873 suspension versus tablet formulations in early-phase studies?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇸🇬Singapore, Singapore
Pfizer Investigational Site🇸🇬Singapore, Singapore